Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Fortress Biotech (FBIO) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Fortress Biotech (FBIO) over the last 12 years, with Q3 2025 value amounting to 38.63%.

  • Fortress Biotech's EBITDA Margin rose 1124000.0% to 38.63% in Q3 2025 from the same period last year, while for Sep 2025 it was 143.55%, marking a year-over-year increase of 261500.0%. This contributed to the annual value of 191.38% for FY2024, which is 229500.0% down from last year.
  • As of Q3 2025, Fortress Biotech's EBITDA Margin stood at 38.63%, which was up 1124000.0% from 222.22% recorded in Q2 2025.
  • In the past 5 years, Fortress Biotech's EBITDA Margin registered a high of 38.63% during Q3 2025, and its lowest value of 473.63% during Q1 2023.
  • For the 5-year period, Fortress Biotech's EBITDA Margin averaged around 226.23%, with its median value being 236.77% (2021).
  • Examining YoY changes over the last 5 years, Fortress Biotech's EBITDA Margin showed a top increase of 2673700bps in 2023 and a maximum decrease of -2760500bps in 2023.
  • Fortress Biotech's EBITDA Margin (Quarter) stood at 339.25% in 2021, then grew by 2bps to 333.05% in 2022, then skyrocketed by 70bps to 98.34% in 2023, then crashed by -60bps to 157.64% in 2024, then surged by 75bps to 38.63% in 2025.
  • Its EBITDA Margin was 38.63% in Q3 2025, compared to 222.22% in Q2 2025 and 169.85% in Q1 2025.